Could trastuzumab deruxtecan become the new standard of care for pretreated HER2-positive breast cancer patients?

Bookmark and Share
Published: 18 Dec 2019
Views: 4343
Dr Ian Krop - Dana Farber Cancer Institute, Boston, USA

Dr Ian Krop speaks to ecancer at the 2019 San Antonio Breast Cancer Symposium about the results from the DESTINY-Breast01 study which investigated the effect of the investigational drug trastuzumab deruxtecan in HER2-positive breast cancer patients who have been pretreated with TDM-1.

He outlines the background of this study and describes the use of this agent - which is a HER2-targeted antibody-drug conjugate.

Dr Krop reports the findings from this study, in which patients were treated with the recommended dose of 5.4 mg/kg. An overall response rate of 60.0 percent was achieved, with the occurrence of mostly low-grade treatment-emergent adverse events.

He highlights that 25 patients experienced interstitial lung disease (ILD), which was also seen in prior studies.

Dr Krop believes that this drug could become the new standard of care for these patients.

Watch the press conference here.

Read more about the study here